Answers are grounded in this paper and cite their sources.
From an insurer perspective, routine and algorithmic prescription drug coverage restrictions requiring failure of low-cost behavioral, dietary, and off-label treatments appear cost-effective. Efforts to address insurance coverage and drug pricing are needed so that healthcare providers can optimally care for patients with this common, heterogenous disorder.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: